{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:56:20Z","timestamp":1790646980512,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"DOI":"10.1007\/s00292-026-01596-1","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:54:47Z","timestamp":1790600087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update zum Ovarialkarzinom","Update on ovarian cancer"],"prefix":"10.1007","author":[{"given":"Pauline","family":"Wimberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"7","key":"1596_CR1","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1097\/IGC.0000000000000767","volume":"26","author":"D Querleu","year":"2016","unstructured":"Querleu\u00a0D, Planchamp\u00a0F, Chiva\u00a0L, Fotopoulou\u00a0C, Barton\u00a0D, Cibula\u00a0D et\u00a0al (2016) European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery. Int J Gynecol Cancer 26(7):1354\u20131363","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"1596_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109696","volume":"51","author":"P Wimberger","year":"2025","unstructured":"Wimberger\u00a0P, Pfisterer\u00a0J, du Bois\u00a0A, Hilpert\u00a0F, Kerkmann\u00a0M, Sehouli\u00a0J, Mahner\u00a0S, de Gregorio\u00a0N, Hanker\u00a0L, Heitz\u00a0F, Marm\u00e9\u00a0F, W\u00f6lber\u00a0L, Holtmann\u00a0L, Elser\u00a0G, Harter\u00a0P, AGO Study Group (2025) Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observations. Eur J Surg Oncol 51(6):109696. https:\/\/doi.org\/10.1016\/j.ejso.2025.109696","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"1596_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-025-01843-8","volume":"18","author":"J Hansinger","year":"2025","unstructured":"Hansinger\u00a0J, Schoffer\u00a0O, V\u00f6lkel\u00a0V, Gerken\u00a0M, Wimberger\u00a0P et\u00a0al (2025) Comparison of survival in ovarian cancer patients following treatment in certified gynecologic oncology centers and non-certified hospitals: a German retrospective cohort study (WiZen). J\u00a0Ovarian Res 18(1):238. https:\/\/doi.org\/10.1186\/s13048-025-01843-8","journal-title":"J Ovarian Res"},{"key":"1596_CR4","unstructured":"(2026) S3-Guideline Diagnostics, Therapy and Surveillance of malignant ovarian tumors."},{"issue":"suppl 17","key":"1596_CR5","volume":"43","author":"S Mahner","year":"2025","unstructured":"Mahner\u00a0S, Heitz\u00a0F, Salehi\u00a0S, Reuss\u00a0A, Guyon\u00a0F, du Bois\u00a0A, Harter\u00a0P, Fotopoulou\u00a0C, Querleu\u00a0D, Mosgard\u00a0BJ, Kr\u00e4mer\u00a0B, Raspagliesi\u00a0F, Lampe\u00a0B, Burges\u00a0A, Schmalfeldt\u00a0B, Wimberger\u00a0P, Bronger\u00a0H, Chi\u00a0D, Sehouli\u00a0J, Aletti\u00a0G, the TRUST investigators (2025) TRUST: Trial of Radical Upfront Surgical Therapy in Advanced Ovarian Cancer (ENGOT ov33 \/ AGO-OVAR OP.7). J\u00a0Clin Oncol 43(suppl 17):abstr LBA5500","journal-title":"J Clin Oncol"},{"issue":"3","key":"1596_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro\u00a0P, Banerjee\u00a0S, Colombo\u00a0N, Scambia\u00a0G, Kim\u00a0BG, Oaknin\u00a0A, Friedlander\u00a0M, Lisyanskaya\u00a0A, Floquet\u00a0A, Leary\u00a0A, Sonke\u00a0GS, Gourley\u00a0C, Oza\u00a0A, Gonz\u00e1lez-Mart\u00edn\u00a0A, Aghajanian\u00a0C, Bradley\u00a0W, Mathews\u00a0C, Liu\u00a0J, McNamara\u00a0J, Lowe\u00a0ES, Ah-See\u00a0ML, Moore\u00a0KN, SOLO1 Investigators (2023) Overall Survival With Maintenance Olaparib at a\u00a07-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a\u00a0BRCA Mutation: The SOLO1\/GOG 3004 Trial. J\u00a0Clin Oncol 41(3):609\u2013617","journal-title":"J Clin Oncol"},{"issue":"4","key":"1596_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","volume":"34","author":"D Lorusso","year":"2024","unstructured":"Lorusso\u00a0D, Mouret-Reynier\u00a0MA, Harter\u00a0P, Cropet\u00a0C, Caballero\u00a0C, Wolfrum-Ristau\u00a0P et\u00a0al (2024) Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial. Int J Gynecol Cancer 34(4):550\u2013558","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"1596_CR8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk\u00a0BJ, Barretina-Ginesta\u00a0MP, Pothuri\u00a0B, Vergote\u00a0I, Graybill\u00a0W, Mirza\u00a0MR et\u00a0al (2024) Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol 35(11):981\u2013992","journal-title":"Ann Oncol"},{"issue":"12","key":"1596_CR9","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","volume":"34","author":"E Pujade-Lauraine","year":"2023","unstructured":"Pujade-Lauraine\u00a0E, Selle\u00a0F, Scambia\u00a0G, Asselain\u00a0B, Marm\u00e9\u00a0F, Lindemann\u00a0K et\u00a0al (2023) Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial. Ann Oncol 34(12):1152\u20131164","journal-title":"Ann Oncol"},{"issue":"23","key":"1596_CR10","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore\u00a0KN, Angelergues\u00a0A, Konecny\u00a0GE, Garcia\u00a0Y, Banerjee\u00a0S, Lorusso\u00a0D et\u00a0al (2023) Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med 389(23):2162\u20132174","journal-title":"N Engl J Med"},{"key":"1596_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ijc.21712","volume":"119","author":"LE Kelemen","year":"2006","unstructured":"Kelemen\u00a0LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119:243\u2013250","journal-title":"Int J Cancer"},{"key":"1596_CR12","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","volume":"26","author":"JA Ledermann","year":"2015","unstructured":"Ledermann\u00a0JA, Canevari\u00a0S, Thigpen\u00a0T (2015) Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol 26:2034\u20132043","journal-title":"Ann Oncol"},{"key":"1596_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","volume":"17","author":"M Scaranti","year":"2020","unstructured":"Scaranti\u00a0M, Cojocaru\u00a0E, Banerjee\u00a0S, Banerjii\u00a0U (2020) Exploiting the folate receptor \u03b1 in oncology. Nat Rev Clin Oncol 17:349\u2013359","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1596_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S1470-2045(25)00021-X","volume":"26","author":"T Van Gorp","year":"2025","unstructured":"Van Gorp\u00a0T, Moore\u00a0KN, Konecny\u00a0GE, Leary\u00a0A, Garc\u00eda-Garc\u00eda\u00a0Y, Banerjee\u00a0S et\u00a0al (2025) Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor alpha-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol 26(4):503\u2013515","journal-title":"Lancet Oncol"},{"issue":"suppl_2","key":"1596_CR15","volume":"36","author":"N Colombo","year":"2025","unstructured":"Colombo\u00a0N, Zsiros\u00a0E, Sebastianelli\u00a0A, Bidzinski\u00a0M, Gallardo\u00a0C, Matanes\u00a0E et\u00a0al (2025) Pembrolizumab vs placebo plus weekly paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer: results from the randomized, double-blind phase 3 ENGOT-ov65\/KEYNOTE-B96 study. Annals of Oncology 36(suppl_2):LBA3","journal-title":"Annals of Oncology"},{"key":"1596_CR16","doi-asserted-by":"crossref","unstructured":"Colombo N et al. (2026) Pembrolizumab plus weekly paclitacel in platinum-resistant recurent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): multicentre, randomised, double-blind, phase 3 study. Lancet 407(10538):1525\u20131537","DOI":"10.1016\/S0140-6736(26)00602-1"},{"issue":"10496","key":"1596_CR17","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","volume":"405","author":"AB Olawaiye","year":"2025","unstructured":"Olawaiye\u00a0AB, Gladieff\u00a0L, O\u2019Malley\u00a0DM, Kim\u00a0JW, Garbaos\u00a0G, Salutari\u00a0V et\u00a0al (2025) Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet 405(10496):2205\u20132216","journal-title":"Lancet"},{"issue":"13","key":"1596_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.18632\/oncotarget.27989","volume":"12","author":"AE Greenstein","year":"2021","unstructured":"Greenstein\u00a0AE, Hunt\u00a0HJ (2021) Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells. Oncotarget 12(13):1243\u20131255","journal-title":"Oncotarget"},{"issue":"1","key":"1596_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ygyno.2017.04.012","volume":"146","author":"JT Veneris","year":"2017","unstructured":"Veneris\u00a0JT, Darcy\u00a0KM, Mhawech-Fauceglia\u00a0P, Tian\u00a0C, Lengyel\u00a0E, Lastra\u00a0RR, Pejovic\u00a0T, Conzen\u00a0SD, Fleming\u00a0GF (2017) High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol 146(1):153\u2013160","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1596_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ygyno.2015.06.033","volume":"138","author":"EM Stringer-Reasor","year":"2015","unstructured":"Stringer-Reasor\u00a0EM, Baker\u00a0GM, Skor\u00a0MN, Kocherginsky\u00a0M, Lengyel\u00a0E, Fleming\u00a0GF, Conzen\u00a0SD (2015) Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol 138(3):656\u2013662","journal-title":"Gynecol Oncol"},{"issue":"15","key":"1596_CR21","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-21-4363","volume":"28","author":"PN Munster","year":"2022","unstructured":"Munster\u00a0PN, Greenstein\u00a0AE, Fleming\u00a0GF, Borazanci\u00a0E, Sharma\u00a0MR, Custodio\u00a0JM, Tudor\u00a0IC, Pashova\u00a0HI, Shepherd\u00a0SP, Grauer\u00a0A, Sachdev\u00a0JC (2022) Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clin Cancer Res 28(15):3214\u20133224","journal-title":"Clin Cancer Res"},{"issue":"30","key":"1596_CR22","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1200\/JCO.22.02624","volume":"41","author":"N Colombo","year":"2023","unstructured":"Colombo\u00a0N, Van Gorp\u00a0T, Matulonis\u00a0UA, Oaknin\u00a0A, Grisham\u00a0RN, Fleming\u00a0GF et\u00a0al (2023) Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study. J\u00a0Clin Oncol 41(30):4779\u20134789","journal-title":"J Clin Oncol"},{"key":"1596_CR23","doi-asserted-by":"crossref","unstructured":"Lorusso D et\u00a0al. (2026) ROSELLA: A\u00a0phase\u00a03\u00a0study of relacorilant + nab-paclitaxel in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221\/2023). ESGO congress 2026; abstr 906","DOI":"10.1016\/j.esmoop.2025.105332"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01596-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-026-01596-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01596-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:05:45Z","timestamp":1790643945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-026-01596-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":23,"alternative-id":["1596"],"URL":"https:\/\/doi.org\/10.1007\/s00292-026-01596-1","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"28 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.\u00a0Wimberger: Forschungsfunding f\u00fcr die Institutio von Amgen, Abbvie, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, Lilly. Honoraria f\u00fcr wissenschaftliche Vortr\u00e4ge und Teilnahme an Advisory Boards von Abbvie, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, Eisai, Lilly, Gilead und Daichii Sankyo. T.\u00a0Link: Honoraria f\u00fcr wissenschaftliche Vortr\u00e4ge von Amgen, Roche, MSD, Novartis, Pfizer, Lilly, GSK, Astra Zeneca, Daiichi Sankyo, Stemline, Seagen, abbvie. Advisery Board von MSD, Roche, Pfizer, Lilly, Myriad, Eisai, GSK, Gilead, Daiichi Sankyo, Astra Zeneca. Reiseunterst\u00fctzung von Pfizer, Astra Zeneca, Gilead, Daiichi Sankyo, Stemline, Seagen und MSD.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}